Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Novartis AG will license a messenger RNA-based autoimmune therapy from China’s Abogen Biosciences, in a deal worth as much as $7.8 billion.
Lire l’article complet sur le site source
Bloomberg — Markets (EN)